Darolutamide

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66% • In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer (“mBC”), the objective response rate (“ORR”) was 43% • No patients discontinued gedatolisib due to a treatment-related adverse event (“AE”) in either clinical trial MINNEAPOLIS, June 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced preliminary clinical data for gedatolisib in two early phase clinical trials. Gedatolisib is a multi-target inhibitor that addresses all four class I PI3K isoforms and the mTOR complexes mTORC1 and mTORC2 to induce comprehensive blockade of the PI3K/AKT/mTOR (“PAM”) pathway. Phase 1 Clinical Trial in mCRPCIn the Phase 1 portion of a clinical trial evaluating gedatolisib plus Nubeqa® (darolutamide), an approved androgen receptor inhibitor, 38 patients with mCRPC were randomly assigned to receive 600 mg darolutamide twice daily combined with either 120 mg gedatolisib in Arm 1 or 180 mg gedatolisib in Arm 2. In both arms, gedatolisib was administered once weekly for three weeks, then one week off. Additionally, all patients received prophylactic treatment for stomatitis. The preliminary Phase 1 data set utilized a May 30, 2025 data cut-off. The preliminary efficacy and safety analyses for the combined arms showed: The six-month rPFS was 66%.No patients discontinued treatment due to a treatment-related AE and no dose reductions were required with gedatolisib or darolutamide.No Grade 3 hyperglycemia was reported.Grade 2-3 stomatitis was reported in four (10.5%) patients - three (7.9%) Grade 2 and one (2.6%) Grade 3. Additional preliminary results for the Phase 1 portion of the clinical trial will be presented at a medical conference later this year. “We are very encouraged by this preliminary efficacy and safety data,” said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. “The 66% six-month rPFS rate for this novel combination therapy compares favorably to published data for androgen receptor inhibitors in this setting. With no treatment-related discontinuations and less than 3% of patients experiencing Grade 3 stomatitis, we believe it is important to explore additional dose options for gedatolisib. Available gedatolisib pharmacokinetic (PK) data from other clinical trials in solid tumors suggests a relationship between efficacy and dose levels. Since this preliminary data indicates that the optimal gedatolisib dose for patients with mCRPC may not yet have been reached, the company amended the clinical trial protocol to enable exploration of additional doses in the Phase 1/1b portion of this clinical trial to determine the recommended Phase 2 dose.” In the amended Phase 1 portion of the clinical trial, up to six patients are planned to be enrolled in each of three arms and treated with different doses. Upon completion of Phase 1, up to an additional 40 patients will be randomly assigned to up to four Phase 1b cohorts to determine the recommended Phase 2 dose (“RP2D”). Dose levels will be selected based on the results from the Phase 1 clinical trial. In the Phase 2 dose expansion study, which will include subjects from the Phase 1/1b clinical trial, up to 18 additional subjects will be enrolled to achieve a total of approximately 30 subjects treated with the RP2D. All patients will also receive standard doses of darolutamide. Phase 2 Clinical Trial in HER2+ Metastatic Breast CancerIn this investigator-sponsored Phase 2 clinical trial, 44 patients with HER2+/PIK3CA mutated mBC were treated with gedatolisib plus standard doses of trastuzumab-pkrb. No prophylaxis for stomatitis was administered. The median number of prior anti-HER2 therapies enrolled patients received in the metastatic setting was four or more; 86% of patients had received at least three prior anti-HER2 therapies. The data cut-off was February 10, 2025. Key efficacy and safety results, as presented at the American Society of Clinical Oncologists meeting in June 2025, showed: The ORR among all patients enrolled was 43%.Median PFS was 6.0 months (95% CI, 5.0-7.7).Median overall survival was 24.7 months (95% CI; 17.3-NA).No patients discontinued gedatolisib due to a treatment-related AE.One (2.3%) patient experienced Grade 3 hyperglycemia. “The 43% ORR reported in patients who received at least three prior lines of anti-HER2 treatment for their disease is very encouraging and compares favorably to published data for other available therapies in this group of patients,” said Dr. Gorbatchevsky. “The regimen was well tolerated, and no patients discontinued gedatolisib due to treatment-related AEs. While additional clinical studies are needed, this data suggests gedatolisib in combination with HER2 targeted therapy may be an effective and well tolerated therapeutic option for patients with HER2+ mBC.” About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X. Forward-Looking Statements This press release contains statements that constitute "forward-looking statements" including, but not limited to, the size and design of our clinical trials; the timing of initiating and enrolling patients in, and receiving data from, our clinical trials; the impact of clinical trial data on our gedatolisib development program; the costs and expected results from any ongoing or planned clinical trials; the market opportunity for gedatolisib; the ability of our clinical trial data to support the filing of a new drug application; our expectations regarding our ability to obtain U.S. Food and Drug Administration approval to commercialize gedatolisib; revenue expectations; our strategy, marketing and commercialization plans, including the benefits of strategic decisions regarding studies and trials; other expectations with respect to gedatolisib; our anticipated use of cash; and the strength of our balance sheet. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends" or "continue," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond our control. These include, but are not limited to, unforeseen delays in our clinical trials, our ability to obtain and maintain regulatory approvals to commercialize our products and the market acceptance of such products, the development of therapies and tools competitive with our products, our ability to access capital upon favorable terms or at all, and those risks set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 31, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. View source version of release on GlobeNewswire.com Contacts: Celcuity Inc.Brian Sullivan, bsullivan@celcuity.comVicky Hahne, vhahne@celcuity.com(763) 392-0123 ICR HealthcarePatti Bank, patti.bank@icrhealthcare.com(415) 513-1284

一、RSV 防控领域：Moderna 与 Merck 的双重突破6 月 13 日，Moderna 的 mRNA RSV 疫苗 mResvia 获 FDA 批准扩大适应症，将接种人群扩展至 18-59 岁的高危成人。这一决策基于 III 期试验数据，显示该疫苗在年轻高危群体中中和抗体滴度达老年人群的 90%。但分析师指出，真正的市场考验在于 CDC 免疫实践咨询委员会（ACIP）的推荐意见 —— 尤其是在新任 ACIP 主席、疫苗怀疑论者 Dr. Robert Malone 的领导下，审批后的接种指南可能面临限制。值得注意的是，HHS 部长 Robert F. Kennedy Jr. 此前罢免全部 17 名 ACIP 成员并重组委员会，其中两名成员曾公开反对 mRNA 技术，这为 mResvia 的临床推广蒙上阴影。Merck 则在 6 月 10 日凭借 RSV 单克隆抗体 clesrovimab（商品名 Enflonsia）打入婴幼儿市场。该药物通过 CLEVER 试验证实，可将新生儿 RSV 相关下呼吸道感染风险降低 60.5%，住院率减少 84.3%。其独特的 105mg 固定剂量方案无需根据体重调整，配合长达 5 个月的保护期，直接对标 Sanofi 与阿斯利康的 Beyfortus。6 月 26 日，ACIP 投票建议为 8 个月以下未获母源抗体保护的婴儿接种 Enflonsia，为 Merck 抢占约 200 万新生儿市场铺平道路。二、肿瘤治疗领域：争议审批与突破性疗法并存UroGen 的 Zusduri（丝裂霉素膀胱内注射剂）获批成为六月最具争议的审批事件。尽管 FDA 肿瘤药物咨询委员会以 5:4 的微弱劣势反对该申请，认为 ENVISION 试验缺乏随机对照且随访时间不足，但 FDA 最终基于 80.6% 的 18 个月持续缓解率数据批准其用于低级别中危非肌层浸润性膀胱癌。这是该适应症首个获批疗法，预计 7 月上市后将挑战现有卡介苗（BCG）疗法的主导地位。UroGen 承诺完成 ENVISION 试验以补充数据，此举被视为 FDA 在未满足医疗需求领域的灵活审批范例。Nuvation Bio 的 ROS1 抑制剂 taletrectinib（Ibtrozi）则凭借 TRUST 系列试验的惊艳数据获加速批准。在未接受过酪氨酸激酶抑制剂（TKI）的患者中，客观缓解率达 90%，脑转移患者颅内缓解率 73%。尽管单臂试验设计未纳入无进展生存期数据，但 Jefferies 分析师指出，该药物在 ROS1 阳性非小细胞肺癌（NSCLC）中的突破，或将重塑靶向治疗格局。Ibtrozi 作为 Nuvation 首款商业化产品，其上市进度将直接影响公司估值。三、多领域审批亮点：从前列腺癌到肝炎的全面覆盖Bayer 的 Nubeqa 在 6 月 4 日获批单药用于转移性去势敏感前列腺癌（mCSPC），打破此前需与多西他赛联合使用的限制。ARANOTE 试验显示，Nubeqa 联合雄激素剥夺治疗（ADT）使高负荷肿瘤患者疾病进展风险降低 40%，低负荷患者降低 70%。2024 年该药物已为 Bayer 带来 17.5 亿美元收入，新适应症预计将推动年销售额突破 20 亿美元。Beigene（现 BeOne）的 Brukinsa 片剂剂型获批则提升了用药便利性。160mg 片剂可替代原有的 80mg 胶囊，实现每日两次给药，成为首个兼具灵活给药方案的 BTK 抑制剂。生物等效性试验显示，片剂与胶囊在健康受试者中的药代动力学特征一致，预计 2025 年 10 月完成剂型替换。AbbVie 的 Mavyret 成为首个获批用于急性丙型肝炎的药物，8 周疗程的持续病毒学应答率达 96%。该适应症扩展基于 300 例初治患者的单臂试验，填补了急性 HCV 治疗的空白。尽管 2024 年 Mavyret 销售额同比下降 7% 至 13 亿美元，新适应症有望重新激活这一直接抗病毒药物的市场潜力。四、行业影响与未来展望六月的审批潮凸显 FDA 在公共卫生需求与科学严谨性间的平衡策略。RSV 领域的双雄并立（Moderna 疫苗 vs Merck 抗体）将引发市场细分竞争，而 UroGen 的争议获批或为同类 “单臂试验 + 高缓解率” 药物树立审批先例。值得关注的是，阿斯利康与第一三共的 Datroway（TROP2 ADC）凭借 45% 的客观缓解率获加速批准用于 EGFR 突变 NSCLC，但其后续确证性试验的成败将决定该类 ADC 药物的监管走向。随着 FDA 在 AI 工具 Elsa 争议中加速审批流程，下半年肿瘤免疫、基因治疗等领域的突破性疗法审批可能增多。但行业普遍认为，在 ACIP 重组与医保谈判压力下，创新药的市场准入挑战将与审批突破同步增加，真正的商业成功仍需跨越临床指南、支付政策等多重障碍。参考来源：https://www.biospace.com/fda/moderna-merck-urogen-score-rsv-and-cancer-nods-in-june识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。